期刊文献+

某院住院患者抑酸药使用分析

Application analysis of the Acid-Suppressive drugs used in inpatients in one hospital
下载PDF
导出
摘要 目的:分析某院医院住院患者抑酸药的应用情况,为临床合理用药提供参考。方法:随机抽查该院2014年1月至12月期间住院患者抑酸药使用情况,统计抑酸药消耗数量、金额及科室分布,对累积用药频度(DDDs)、使用强度、使用率、年人均费用及使用目的等进行统计分析。结果:住院患者抑酸药品种以质子泵抑制剂(Proton Pump Inhibitors,PPI)占主导地位,主要采用静脉给药。内科系统DDDs占59.18%,主要是消化、呼吸、心内、肾内等;外科占40.82%,主要是普外一科、普外二科和泌外科。使用强度排名,前5位的是消化科、普外一科、普外二科、泌外科和ICU。住院患者使用率为42.00%;人均费用442.17元。结论:PPI在住院患者中使用非常广泛,但存在一定的不合理性,有待规范。 Objective: To analyze the application of the acid-suppressive drugs in the inpatients in one hospital and provide reference for the clinical rational use of drugs. Mothods: Randomized sampling the application of the acid-suppressive drugs in the inpatients monthly from January to December 2014, the consumption quantity, sales amount, department distribution, DDDs, use intensity, utilization rate of acid-suppressive drugs, per capita costs and indications were performed the statistics analysis. Results: The proton pump inhibitors (PPI)were predominant in the acid-suppressive drugs used in inpatients and mainly adopted the intravenous administration. The percentage of use frequency in internal medicine was 59.18%, involving the digestion, respiration, cardiology, nephrology, etc. Surgery was 40.82%, mainly involving 1 st general surgery, 2nd general surgery and urology. The TOP5 of use intensity were digestion, 1st general surgery, 2rid general surgery, urology and ICU. The inpatients' utilization rate was 42.00%. Per capita costs were 442.17 CNY. Conclusions: PPI was used widely in inpatients, but there were some unreasonable aspects need to be standardized.
出处 《药品评价》 CAS 2015年第20期26-29,共4页 Drug Evaluation
关键词 抑酸药 质子泵抑制剂 合理用药 Acid-suppressive Drugs PPI Rational Drug Use
  • 相关文献

参考文献8

二级参考文献27

  • 1Soumana C Nasser,Jeanette G Nassif,Hani I Dimassi.Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients[J].World Journal of Gastroenterology,2010,16(8):982-986. 被引量:23
  • 2杨日芳,恽榴红,丁振.质子泵抑制剂的研究进展[J].中国新药杂志,1994,3(6):3-9. 被引量:26
  • 3许铁男.抗溃疡药 兰索拉唑[J].国外医药(合成药.生化药.制剂分册),1995,16(4):245-247. 被引量:15
  • 4高晓红,潘伯荣.新型质子泵抑制剂-兰索拉唑[J].新消化病学杂志,1996,4(3):158-159. 被引量:25
  • 5崔银珠.抗溃疡药Leminoprazole[J].国外医药合成药、生化药、制剂分册,1997,3(18):184-185.
  • 6Spirt MJ. Stress-related mucosal disease: risk factors and prophylactic therapy[J]. Clin Ther, 2004, 26(2): 197-213.
  • 7Lev R, Molot MD, McNamara J, et al. "Stress" ulcers following war wounds in Vietnam. A morphologic and histochemical study [J]. Lab Invest, 1971, 25(6) : 491-502.
  • 8Cook DJ, Fuller HD, Guyan GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group[J]. N Engl J Med, 1994, 330(6):377-381.
  • 9Allen ME, Kopp B J, Erstad BL. Stress ulcer prophylaxis in the postoperative period [J].Am J Health Syst Pharm, 2004, 61(6): 588-596.
  • 10ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP commission on therapeutics and approved by the ASHP board of directors on november 14, 1998 [J]. Am J Health Syst Pharm, 1999, 56(4): 347-379.

共引文献1289

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部